Familial clustering of esrd in the norwegian population

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 10, 2014, Pages 1692-1700

  Skrunes, Rannveig ^a   Svarstad, Einar ^a,b   Reisæter, Anna Varberg ^c   Vikse, Bjørn Egil ^b,d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HAUGESUND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC PYELONEPHRITIS; CLUSTER ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; FAMILY HISTORY; FEMALE; FOLLOW UP; GLOMERULOPATHY; HUMAN; INCIDENCE; INTERSTITIAL NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; NORWAY; OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; ADOLESCENT; CHILD; GENETIC PREDISPOSITION; GENETICS; HEREDITY; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PEDIGREE; PHENOTYPE; REGISTER; RISK ASSESSMENT; TIME; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CLUSTER ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NORWAY; PEDIGREE; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84923809108     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01680214     Document Type: Article

References (24)

1. O’Dea DF, Murphy SW, Hefferton D, Parfrey PS: Higher risk for renal failure in first-degree relatives of white patients with endstage renal disease: a population-based study. Am J Kidney Dis 32: 794–801, 1998
2. Freedman BI, Volkova NV, Satko SG, Krisher J, Jurkovitz C, Soucie JM, McClellan WM: Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol 25: 529–535, 2005
3. Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, Bernhardy AJ, Needham AW, Lazarus R, Pollak MR: A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 78: 698–704, 2010
4. Andersen PK, Gill RD: Cox’s regression model for counting processes: A large sample study. Ann Stat 10(4): 1100–1120, 1982
5. D’Agati VD, Kaskel FJ, Falk RJ: Focal segmental glomerulosclerosis. N Engl J Med 365: 2398–2411, 2011
6. Spink C, Stege G, Tenbrock K, Harendza S: The CTLA-4 +49GG genotype is associated with susceptibility for nephrotic kidney diseases. Nephrol Dial Transplant 28: 2800–2805, 2013
7. Freedman BI, Bostrom M, Daeihagh P, Bowden DW: Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol 2: 1306–1316, 2007
8. Barratt J, Feehally J: IgA nephropathy. J Am Soc Nephrol 16: 2088–2097, 2005
9. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators: APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369[Feldman]: 2183–2196, 2013
10. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB; SK Investigators: Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83: 114–120, 2013
11. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH: APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24: 1484–1491, 2013
12. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA: APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22: 2129–2137, 2011
13. Freedman BI, Murea M: Target organ damage in African American hypertension: Role of APOL1. Curr Hypertens Rep 14: 21–28, 2012
14. van Dijk PCW, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW, Grönhagen-Riska C, Kramar R, Leivestad T, Simpson K, Briggs JD; ERA-EDTA registry: Renal replacement therapy in Europe: The results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 16: 1120–1129, 2001
15. Spray BJ, Atassi NG, Tuttle AB, Freedman BI: Familial risk, age at onset, and cause of end-stage renal disease in white Americans. J Am Soc Nephrol 5: 1806–1810, 1995
16. United States Renal Data System: 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Volume 2. Available at: www.usrds.org/atlas.aspx2013. Accessed December 10, 2013
17. Leivestad T: Annual Report 2012, The Norwegian Renal Registry. Available at: http://www.nephro.no/nnr/AARSM2012.pdf2012. Accessed September 13, 2013
18. McClellan W, Speckman R, McClure L, Howard V, Campbell RC, Cushman M, Audhya P, Howard G, Warnock DG: Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. J Am Soc Nephrol 18: 1344–1352, 2007
19. Freedman BI, Soucie JM, McClellan WM: Family history of endstage renal disease among incident dialysis patients. J Am Soc Nephrol 8: 1942–1945, 1997
20. Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, Kopp JB, Winkler CA, Nelson GW, Johnson RC, Palmer ND, Hicks PJ, Bostrom MA, Cooke JN, McDonough CW, Bowden DW: Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet 7: e1002150, 2011
21. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175–1184, 2008
22. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR: The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 21: 1422–1426, 2010
23. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39: 940–945, 1996
24. Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 21: 1819–1834, 2010